Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia28 April 2014Corporate and M&A Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryGlobal 100 2025: elite tier set the pace as powerhouse firms pull awayFreshfields accounts reveal 6% revenue rise for 2024-25 as US sees fastest growthRevolving Doors: Latham swipes German transactions team from Freshfields as Ropes rebuilds in private equity‘There are winners and losers’ – Hogan Lovells and Cadwalader’s leaders on why their merger makes senseA merger or a takeover? Winston Taylor by the numbers‘History in the making’ – Hogan Lovells set for record $3.6bn merger with CadwaladerRevolving doors: Simpson Thacher, Latham, Sidley lead New Year London moves‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryFive partners vie to succeed Hoyland as Simmons managing partner